Compare Charles River Laboratories Intl. Inc (CRL) vs T-Mobile Us Inc (TMUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs T-Mobile Us Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $227.69 (market cap $11.14B), while T-Mobile Us Inc trades at $188.3 (market cap $202.51B). The key difference: T-Mobile Us Inc is far larger — about 18.2× Charles River Laboratories Intl. Inc's market cap, and T-Mobile Us Inc pays a 2.18% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | TMUS | |
|---|---|---|
Market Cap | $11.14B | $202.51B |
Sector | Health | Media |
52-Week High | $233.60 | $259.01 |
52-Week Low | $145.57 | $167.65 |
Enterprise Value | $14.00B | $320.21B |
Dividend Yield | — | 2.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
T-Mobile US (TMUS) trades at $188.42, up 0.43% today, with a bullish technical signal and strong analyst support. The stock shows robust fundamentals with 2025 revenue of $88.31B and net income of $10.99B, though profit margins dipped slightly. Recent leadership changes and competitive threats from Starlink are in focus, while cash flow remains positive. The consensus price target is $243.09, implying significant upside.
Outlook remains positive given earnings beats and growth prospects, but risks include rising debt levels and satellite competition. Institutional sentiment is strongly bullish with 83% buy ratings, supporting a favorable risk-reward profile for long-term investors despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →
